Mylan secures DCGI approval in India for pretomanid, a treatment for highly drug-resistant forms of TB

Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be approved in more than 40 years

Approval comes as a result of Mylan’s global collaboration with non-profit drug development partner TB Alliance

Read More →

Otsuka and Mylan announce license agreement to commercialize delamanid (Deltyba™) for MDR-TB in high-burden countries

TOKYO, HERTFORDSHIRE, England and PITTSBURGH, Aug. 24, 2017 -- Otsuka Pharmaceutical Co. Ltd. (Otsuka) and Mylan N.V. (NASDAQ, TASE: MYL) have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited (Mylan), to commercialize delamanid for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries. Delamanid was discovered and developed, and is currently marketed by Otsuka under the brand name Deltyba™.

Read More →

Page 1 of 1 · Total posts: 2